CepTor Corporation to Present at the Wall Street Analyst Forum.HUNT VALLEY, Md. -- CepTor Corporation (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CEPO CEPO County Emergency Planning Officer (UK) CEPO Community & Environment Project Office (Edmonton Green, North London) ) today announced that it will be participating in the Wall Street Analyst Forum, to be held February 28 - March 2, 2005 at the Roosevelt Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . William Pursley, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CepTor, is scheduled to speak on Monday, February 28, 2005 at 12:30PM EST EST electroshock therapy. EST abbr. electroshock therapy and is expected to discuss the Company's product pipeline, strategic initiatives and market opportunities. CepTor's audio presentation will be broadcast live over the Internet. To access the audio webcast, please log onto http://www.vcall.com/CEPage.asp?ID=90856. The link will be active for up to 12 months and is for both the live event and the archive. About CepTor CepTor Corporation is a biopharmaceutical company focusing on the development of proprietary, cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy Duchenne's muscular dystrophy, n an X-linked recessive condition pres-ent at birth in which the muscles of the pelvis and legs waste away in a symmetric fashion. . The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy. This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion